Currently out of the existing stock ratings of Pete Stavropoulos, 40 are a BUY (97.56%), 1 are a HOLD (2.44%).

Pete Stavropoulos

Work Performance Price Targets & Ratings Chart

Analyst Pete Stavropoulos, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 31.11% that have a potential upside of 69.16% achieved within 159 days.

Pete Stavropoulos’s has documented 69 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VERA, Vera Therapeutics at 07-May-2025.

Wall Street Analyst Pete Stavropoulos

Analyst best performing recommendations are on ORTX (ORCHARD THERAPEUTICS PLC).
The best stock recommendation documented was for ORTX (ORCHARD THERAPEUTICS PLC) at 6/27/2023. The price target of $15 was fulfilled within 100 days with a profit of $9.77 (186.81%) receiving and performance score of 18.68.

Average potential price target upside

ANNX Annexon  PLRX Pliant Therapeutics  ARCT Arcturus Therapeutics Holdings ORTX Orchard Therapeutics PLC RZLT Rezolute ABOS Acumen Pharmaceuticals ALEC Alector VERA Vera Therapeutics VSTM Verastem VYGR Voyager Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

5 months 5 days ago
(13-May-2025)

0/11 (0%)

$9.88 (161.44%)

Buy

5 months 5 days ago
(13-May-2025)

0/3 (0%)

$23.88 (390.20%)

Buy

11 months 3 days ago
(15-Nov-2024)

0/5 (0%)

$10.05 (340.68%)

Buy

$14

$10.85 (344.44%)

$10

1 years 4 months 13 days ago
(05-Jun-2024)

0/4 (0%)

$7.21 (106.19%)

Buy

$12

$8.85 (280.95%)

$10

1 years 4 months 14 days ago
(04-Jun-2024)

4/6 (66.67%)

$6.01 (100.33%)

106

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Pete Stavropoulos is most bullish on?

Potential upside of $68.77 has been obtained for VERA (VERA THERAPEUTICS)

What Year was the first public recommendation made by Pete Stavropoulos?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?